These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26853320)

  • 21. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection.
    Martina P; Feliziani S; Juan C; Bettiol M; Gatti B; Yantorno O; Smania AM; Oliver A; Bosch A
    Int J Med Microbiol; 2014 Nov; 304(8):1182-91. PubMed ID: 25217078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.
    Salsgiver EL; Fink AK; Knapp EA; LiPuma JJ; Olivier KN; Marshall BC; Saiman L
    Chest; 2016 Feb; 149(2):390-400. PubMed ID: 26203598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Isolated pathogen microorganisms in respiratory samples from children with cystic fibrosis].
    Anzaudo MM; Busquets NP; Ronchi S; Mayoral C
    Rev Argent Microbiol; 2005; 37(3):129-34. PubMed ID: 16323660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cystic fibrosis lung microbiome.
    Surette MG
    Ann Am Thorac Soc; 2014 Jan; 11 Suppl 1():S61-5. PubMed ID: 24437409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.
    Caverly LJ; Zhao J; LiPuma JJ
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S31-8. PubMed ID: 26335953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Isolation frequency of Burkholderia cepacia from cystic fibrosis patients].
    Ocak F; Gözalan A; Ozçelik U; Anadol D; Kiper N; Aktepe OC; Göçmen A; Esen B
    Mikrobiyol Bul; 2002 Jan; 36(1):1-10. PubMed ID: 12476760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial overview: clinical utility of synergy testing for multidrug resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Middleton PG
    Paediatr Respir Rev; 2007 Sep; 8(3):262-3, quiz 263-4. PubMed ID: 17868925
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy.
    Levy J
    Chest; 1988 Aug; 94(2 Suppl):150S-156S. PubMed ID: 3135160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis.
    Foweraker J
    Br Med Bull; 2009; 89(1):93-110. PubMed ID: 19155262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
    Murray TS; Stanley G; Koff JL
    Clin Chest Med; 2022 Dec; 43(4):667-676. PubMed ID: 36344073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing Pulmonary Infection in Adults With Cystic Fibrosis: Adult Cystic Fibrosis Series.
    Green HD; Jones AM
    Chest; 2022 Jul; 162(1):66-75. PubMed ID: 35167860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary infections in children with cystic fibrosis.
    Stutman HR; Marks MI
    Semin Respir Infect; 1987 Sep; 2(3):166-76. PubMed ID: 3317617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
    Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
    J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis.
    Renders N; Verbrugh H; Van Belkum A
    Infect Genet Evol; 2001 Jul; 1(1):29-39. PubMed ID: 12798048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2008)].
    Goto H; Iwasaki M
    Jpn J Antibiot; 2015 Feb; 68(1):19-36. PubMed ID: 25980051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular typing of the bacterial flora in sputum of cystic fibrosis patients.
    Kolak M; Karpati F; Monstein HJ; Jonasson J
    Int J Med Microbiol; 2003 Aug; 293(4):309-17. PubMed ID: 14503795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging cystic fibrosis pathogens and the microbiome.
    Mahenthiralingam E
    Paediatr Respir Rev; 2014 Jun; 15 Suppl 1():13-5. PubMed ID: 24832700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE; Mastoridis P
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on antibiotics for infection control in cystic fibrosis.
    Kirkby S; Novak K; McCoy K
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):967-80. PubMed ID: 19803706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections.
    Tümmler B; Kiewitz C
    Mol Med Today; 1999 Aug; 5(8):351-8. PubMed ID: 10431168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.